GK3P Inhibitors

The GK3P inhibitors can be categorized into two main groups: those affecting cellular metabolism and those influencing lipid metabolism. The first category, including Dichloroacetate, 3-Bromopyruvate, and WZB117, tends to shift metabolic pathways away from glycolysis or gluconeogenesis. This, in turn, reduces the availability of glycerol, a crucial substrate for GK3P. By controlling the metabolic intermediates, these compounds ensure that the flux of glycerol towards GK3P is minimized. For instance, Dichloroacetate affects pyruvate dehydrogenase kinase and thus alters the metabolic flux towards oxidative phosphorylation, depriving GK3P of its glycerol substrate. Similarly, 3-Bromopyruvate targets hexokinase II, another key enzyme in the glycolytic pathway, which indirectly reduces glycerol availability for GK3P.

The second category focuses on altering lipid metabolism, which indirectly affects GK3P's substrate availability or enzymatic function. Compounds like Cerulenin and Rapamycin inhibit fatty acid synthesis and mTOR signaling respectively, thereby reducing triglyceride synthesis. With decreased triglyceride levels, the availability of glycerol for GK3P also drops. Retinoic Acid and DHEA, although structurally different, share this functional property. They affect the lipid metabolism by either regulating it at the transcriptional level or by inhibiting key enzymes like G6PD. By doing so, they can affect the cellular redox status and NADPH/NADP+ ratios, which may be crucial for GK3P function.